MY194920A - Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof - Google Patents
Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereofInfo
- Publication number
- MY194920A MY194920A MYPI2016701265A MYPI2016701265A MY194920A MY 194920 A MY194920 A MY 194920A MY PI2016701265 A MYPI2016701265 A MY PI2016701265A MY PI2016701265 A MYPI2016701265 A MY PI2016701265A MY 194920 A MY194920 A MY 194920A
- Authority
- MY
- Malaysia
- Prior art keywords
- polysaccharide
- protein
- protein conjugates
- present
- enhanced immunogenicity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Materials Engineering (AREA)
- Pulmonology (AREA)
- Sustainable Development (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to polysaccharide ? protein conjugates with enhanced immunogenicity displaying significantly high antibody titres. The carrier protein is obtained from group of gram positive bacteria, polysaccharide fragment is obtained from group of gram negative bacteria, preferably from Haemophilus influenzae serotype b (Hib), Neisseria meningitidis serogroup A and C (MenA and MenC). The present invention also relates to a rapid and high yielding process of preparing the polysaccharide?protein conjugates in which derivatized carrier protein reacts with cleaved and depolymerized polysaccharide fragments of optimum length to obtain polysaccharide ? protein conjugate employing reductive amination chemistry. The present invention further relates to a chemical process of polysaccharide fragmentation to optimum length for use in conjugation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2363DE2014 | 2014-08-20 | ||
IN3047DE2013 IN2013DE03047A (en) | 2013-10-11 | 2014-10-10 | |
PCT/IB2014/065201 WO2015052684A2 (en) | 2013-10-11 | 2014-10-10 | Polysaccharide-protein conjugates with enhanced immunogenicity and rapid high yielding process thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MY194920A true MY194920A (en) | 2022-12-23 |
Family
ID=52144766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2016701265A MY194920A (en) | 2013-10-11 | 2014-10-10 | Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN105636608A (en) |
MY (1) | MY194920A (en) |
WO (1) | WO2015052684A2 (en) |
ZA (1) | ZA201602375B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105770890A (en) * | 2016-03-08 | 2016-07-20 | 苏文全 | Specific protein composition and application method thereof |
CN106084037B (en) * | 2016-06-08 | 2020-01-07 | 中国人民解放军第二军医大学 | Bacillus anthracis capsule surface trisaccharide conjugate and preparation method and application thereof |
KR20190044663A (en) | 2016-09-02 | 2019-04-30 | 사노피 파스퇴르 인크 | Neisseria meningitis vaccine |
JP6944946B2 (en) * | 2016-10-20 | 2021-10-06 | Kmバイオロジクス株式会社 | Method for Producing Hib Conjugate Vaccine Using Low Molecular Weight PRP |
CN114965784B (en) * | 2022-06-01 | 2023-10-27 | 艾美探索者生命科学研发有限公司 | Method for measuring polysaccharide activation degree |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3828145B2 (en) * | 1993-09-22 | 2006-10-04 | ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | A method for the activation of soluble carbohydrates using a novel cyanating reagent for the production of immunogenic components |
US8048432B2 (en) * | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
GB201103836D0 (en) * | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
-
2014
- 2014-10-10 MY MYPI2016701265A patent/MY194920A/en unknown
- 2014-10-10 CN CN201480056001.6A patent/CN105636608A/en active Pending
- 2014-10-10 WO PCT/IB2014/065201 patent/WO2015052684A2/en active Application Filing
-
2016
- 2016-04-08 ZA ZA2016/02375A patent/ZA201602375B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2015052684A3 (en) | 2015-07-23 |
WO2015052684A2 (en) | 2015-04-16 |
ZA201602375B (en) | 2017-07-26 |
CN105636608A (en) | 2016-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY194920A (en) | Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof | |
MX2020002558A (en) | Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein. | |
EA201391788A1 (en) | VACCINE CONTAINING CONJUGATES OF CAPSULAR POLYSACCHARIDES STREPTOCOCCUS PNEUMONIAE | |
MX2021014710A (en) | An immunogenic serotype 35b pneumococcal polysaccharide-protein conjugate and conjugation process for making the same. | |
MX2014009250A (en) | Immunogenic composition. | |
CY1112677T1 (en) | COUNCIL PULMONIC COGNACULAR COGNAC GULF Vaccine | |
PH12018501517A1 (en) | Neisseria meningitidis compositions and methods thereof | |
WO2015012904A3 (en) | Antibody-sn-38 immunoconjugates with a cl2a linker | |
PH12015500390B1 (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
MX2013013111A (en) | Multiple antigen presenting immunogenic composition, and methods and uses thereof. | |
EP2601969A3 (en) | Norovirus vaccine formulations | |
BRPI0413323B8 (en) | method for preparing a meningococcal tetanus toxoid conjugate vaccine in commercial volumes | |
MX351345B (en) | Conjugation process of bacterial polysaccharides to carrier proteins. | |
TN2014000148A1 (en) | Antigen binding protein and its use as addressing product for the treatment of cancer | |
CL2011002369A1 (en) | An immunogenic composition comprising: a conjugated pneumococcal capsular saccharide, including depolymerized saccharide of serotype 18c; and meningococcal factor h (fhbp) binding protein antigen, but not including meningococcal membrane vesicles. and method of preparation of the composition. | |
AR080122A1 (en) | COMPOSITION OF CONJUGATED VACCINE OF POLISACARIDO-PROTEIN NEUMOCOCICA 15-VALENTE | |
CL2007003781A1 (en) | Method for the preparation of an immunogenic conjugate comprising the polysaccharide of streptococcus pneumoniae serotype 1 covalently linked to a carrier protein; and process for preparing a multivalent polysaccharide-protein immunogenic composition. | |
JO2840B1 (en) | Vaccine | |
WO2009060281A3 (en) | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties | |
WO2011156774A3 (en) | Multivalent glycopeptide constructs and uses thereof | |
MX2018010920A (en) | Novel polysaccharide-protein conjugates and process to obtain thereof. | |
TN2017000126A1 (en) | An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof | |
IN2013DE03047A (en) | ||
EA201391202A1 (en) | METHOD FOR PREPARING MULTIPLE ANTIGENE GLYKOPEPTID-CARBON CONJUGATES | |
IN2014MU00349A (en) |